Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2016, Vol. 38 ›› Issue (1): 88-92.doi: 10.3881/j.issn.1000-503X.2016.01.016

• Orginal Article • Previous Articles     Next Articles

Clinical Outcome of 131I Therapy in Differentiated Thyroid Cancer with Preablative Thyroglobulin below 10 ng/ml

Xin-feng LIU1, Jiao LI2, Teng ZHAO2, Min HOU1, Hui LI1, Jun LIANG2(), Yan-song LIN1()   

  1. 1Department of Nuclear Medicine,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
    2Department of Oncology,the Affiliated Hospital of Qingdao University,Qingdao,Shandong 266003,China
  • Received:2015-03-02 Online:2016-01-15 Published:2016-03-02
  • Supported by:
    Supported by the National Natural Sciences Foundation of China (30970850)and the Ministry of Health Industry Special Scientific Research Project (201202012)


Objective To investigate the clinical outcome of 131I therapy in differentiated thyroid cancer(DTC) with preablative stimulated thyroglobulin(ps-Tg)below 10 ng/ml and the value of ps-Tg for predicting clinical outcome. Methods Totally 167 DTC patients with ps-Tg below 10 ng/ml were included and divided into three groups [excellent response (ER,n=131),acceptable response (AR,n=34),and incomplete response (IR,n=2)] according to the response to initial 131I therapy. One-way analysis of variance,χ2 test,and Kruskal-Wallis test were used to evaluate the statistical differences of clinicopathological features,recurrence risk,and ps-Tg value among the three groups. The ps-Tg value between ER group and non-ER group were compared by Mann-Whitney rank-sum test. The ROC curve and optimal cut-off point were analyzed to evaluate the clinical value of ps-Tg for predicting disease-free status. Results There was significant difference in ps-Tg level (H=14.305,P=0.001) among three groups but not in age (F=0.831,P=0.755),sex(χ2=0.178,P=0.915),cervical lymph node metastases(χ2=1.475,P=0.478),TNM stage(H=1.063,P=0.588),and recurrence risk (H=2.947,P=0.229). The median level of ps-Tg in ER group was 2.20 ng/ml(1.10,4.40),which was significantly lower than 4.40 ng/ml (2.70,5.90)of non-ER groups (U=1424.50,P=0.000). Area under the ROC curve was 0.717. The cut-off value of ps-Tg was 2.35 ng/ml,with a sensitivity of 83.33%,specificity of 53.43%,and negative predictive value of 92.11%. Conclusion The serum ps-Tg value is a sensitive marker for predicting the disease-free status in DTC patients with ps-Tg below 10 ng/ml.

Key words: differentiated thyroid cancer, thyroglobulin, 131I therapy, clinical outcome

CLC Number: